Apellis says FDA approves SYFOVRE for GA treatment

Apellis Pharmaceuticals announced that the U.S. Food and Drug Administration has approved SYFOVRE for the treatment of geographic atrophy secondary to age-related macular degeneration. SYFOVRE is the first and only FDA-approved treatment for GA, a leading cause of blindness that impacts more than one million people in the U.S. and five million people worldwide. "The approval of SYFOVRE is the most important event in retinal ophthalmology in more than a decade," said Eleonora Lad, M.D., Ph.D., lead investigator for the OAKS study, director of ophthalmology clinical research, associate professor of ophthalmology, Duke University Medical Center. "Until now, there have been no approved therapies to offer people living with GA as their vision relentlessly declined. With SYFOVRE, we finally have a safe and effective GA treatment for this devastating disease, with increasing effects over time."